Alymsys (bevacizumab-maly) vs LY01008
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
Alymsys (bevacizumab-maly)
Marketed by Amneal Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
LY01008
Marketed by Luye Pharma Group
NCT03533127 · Phase 3 · status unknown
This was a randomized, double-blind, active-controlled equivalence trial in 648 patients that measured objective tumor response rate, using the same paclitaxel/carboplatin backbone in both arms. LY01008's response rate was statistically equivalent to bevacizumab's, within the prespecified margin, meeting the trial's own equivalence criterion.
Reported efficacy
Best Objective Response Rate (19 weeks from randomization): LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated. (met)
Result source: NCT03533127
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Alymsys (bevacizumab-maly) | LY01008 |
|---|---|---|
| PFS, median | 8.3 vs 8.6vs AvastinNCT03296163 | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | 40.3% vs 44.6%vs AvastinNCT03296163 | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
PFS, median
- Alymsys (bevacizumab-maly)
- 8.3 vs 8.6vs AvastinNCT03296163
- LY01008
- —Not reported
OS, median
- Alymsys (bevacizumab-maly)
- —Not reported
- LY01008
- —Not reported
ORR
- Alymsys (bevacizumab-maly)
- 40.3% vs 44.6%vs AvastinNCT03296163
- LY01008
- —Not reported
Duration of response, median
- Alymsys (bevacizumab-maly)
- —Not reported
- LY01008
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Alymsys (bevacizumab-maly): 3 of 4 rows · LY01008: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alymsys (bevacizumab-maly) |
|---|---|
| Dropout rate | 34.3%a NCT03296163 · Phase 3 |
| Discontinued due to AEs | —a NCT03296163 · Phase 3 |
| Serious AEs | 18.6%a NCT03296163 · Phase 3 |
| Most frequent reported AEs |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alymsys (bevacizumab-maly)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alymsys (bevacizumab-maly)'s landscape · LY01008's landscape